A composition of chlorine-free poly-oxygenated aluminum hydroxide that comprises a clathrate containing oxygen gas molecules and a nutraceutical. In one embodiment, the poly-oxygenated aluminum hydroxide has particles having a diameter of 212 m or less. The nutraceutical may include one or more of a protein, vitamin, fiber, mineral and electrolytes. The composition may be in a powder or fluid form.

The disclosure provides radiolabeled and/or cytotoxin labelled antibodies and methods and uses of these antibodies. In one embodiment, provided is a cytotoxic agent comprising an antibody that specifically binds a target disease cell surface receptor, a cytotoxin, and a radiolabel, wherein the cytotoxin is linked directly or indirectly to the antibody, and wherein the radiolabel comprises a radionuclide and optionally a scaffold, wherein the scaffold is directly or indirectly coupled to the antibody. Also provided are methods of preparing the cytotoxic agent and methods of treating disease using the cytotoxic agent.

The present invention relates to a nucleic acid-based assembly comprising: at least one nucleic acid aptamer, and at least one nucleic acid motif designed to physically capture a drug. The nucleic acid motif may comprise one or more photo-responsive moieties that effect the release of the drug upon irradiation. The aptamer and the nucleic acid motif each can be covalently linked to one or more lipids, and the lipid-modified aptamer and nucleic acid motif may form the assembly through noncovalent interaction. The invention further relates to use of the nucleic acid-based assembly in the treatment of cancer.

A composition and process to produce poly-oxygenated metal hydroxide particles on the nanometer size scale. The relevant particle size includes all size populations ranging from 1 nanometer (nm) to 3000 nanometers (nm) or 3 micrometer (m) in particle diameter. Filtering may be used to create homogeneous particle sizes. Exemplary delivery applications include inhalation, ingestion, anally, vaginally, dermal penetration or permeation, intramuscular injection, and intravenous injection to treat numerous conditions and diseases of mammals, including humans and animals.

The invention in suitable embodiments is directed to using a purified, clathrin light chain protein for purposes of drug development, enablement, activity, and/or delivery. In one aspect, a man-made, configurable clathrin light chain composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more of a protein sequence, forms one or more type of multifunction nanoscale bio-nanoparticle, such as a biomedical platform, bio-molecular platform, and the like, and using such bio-nanoparticle platforms for development, enablement, and delivery of drugs.

A method of treating a condition of a mammal, including a human individual and an animal, by intravenously administering a therapeutically effective amount of a poly -oxygenated metal hydroxide. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm. The poly-oxygenated metal hydroxide may be 75-90% colloid or crystalline solution with 10-25% addition of poly-oxygenated metal hydroxide particles.

The present invention relates to a method for producing Metal Organic Framework (MOF) having a framework that encapsulates a bio-molecule, the method comprising combining in a solution the bio-molecule and MOF precursors, wherein the bio-molecule promotes formation of the encapsulating framework.

The invention in suitable embodiments is directed to replacement therapeutics. In one aspect, a medicament is comprised in whole or in part of one or more clathrin heavy chain protein that is formed from a plurality of isolated, synthetic or recombinant clathrin protein molecules. In one embodiment, a man-made clathrin heavy chain protein composition replaces and/or modifies cell elements or processes, in vivo or in vitro, thereby treating a disease, condition, or disorder comprising at least one of cell.

Supramolecular inclusion complexes comprising sulfonato methylresorcinarenes according to Formula I and a fluoroquinolone compound are provided. Also provided are pharmaceutical compositions comprising the supramolecular complexes and methods of using the supramolecular complexes to treat bacterial infections, kill or inhibit growth of bacteria, and disrupt bacterial biofilms.

A method of treating a condition of a mammal, including a human individual and an animal, by intravenously administering a therapeutically effective amount of a poly-oxygenated metal hydroxide. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm. The poly-oxygenated metal hydroxide may be 75-90% colloid or crystalline solution with 10-25% addition of poly-oxygenated metal hydroxide particles.